Product
E4/DRSP
Aliases
15 mg estetrol monohydrate/3 mg drospirenone combined oral contraceptive, E4/DRSP 15/3 mg combined tablet
1 clinical trial
1 indication
Indication
SafetyClinical trial
A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics Associated With the Use of a Combined Oral Contraceptive Containing 15 mg Estetrol Monohydrate and 3 mg Drospirenone in Post-menarchal Female Adolescents for 6 CyclesStatus: Completed, Estimated PCD: 2023-11-24